BioCentury | Nov 19, 2014
Financial News

Onxeo proposes EUR 35.4M rights offering

...and Indian rights to Beleodaq, a small molecule histone deacetylase inhibitor. BioAlliance Pharma S.A. and Topotarget A/S...
BioCentury | Oct 6, 2014
Finance

3Q14 Stock Wrap-Up: Going big again

...combination with chlorambucil for first-line CLL in patients unsuitable for fludarabine-based therapy Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI)/Topotarget A/S...
BioCentury | Aug 18, 2014
Company News

Topotarget, BioAlliance deal

...Cancer companies BioAlliance and Topotarget completed their merger in a stock deal. The new company is...
...stock deal. The new company is Onxeo S.A. (Euronext:ONXEO, Paris, France) (see BioCentury, April 21). Topotarget A/S...
BioCentury | Aug 11, 2014
Company News

Innocutis, Onxeo sales and marketing update

...rights to the mucoadhesive formulation of acyclovir from Onxeo. Last month, BioAlliance S.A. merged with Topotarget A/S...
BioCentury | Jul 21, 2014
Company News

BioAlliance, EMS deal

...regulatory milestone payments. The companies could not be reached for details. BioAlliance is merging with Topotarget A/S...
BioCentury | Jul 21, 2014
Company News

Topotarget management update

...Business: Cancer Resigning: Anders Vadsholt as CEO, effective July 31 or until the approval of Topotarget’s...
BioCentury | Jul 14, 2014
Finance

Highlights of weekly biotech stock moves

...payment to partner Topotarget A/S (CSE:TOPO). Spectrum has North American and Indian rights to belinostat from Topotarget...
...company BioAlliance Pharma S.A. (Euronext:BIO). Spectrum finished Independence Day week up $0.89 (11%) to $8.90. Topotarget...
BioCentury | Jul 14, 2014
Financial News

Topotarget completes warrant exercise

Topotarget A/S (CSE:TOPO), Copenhagen, Denmark Business: Cancer Date completed: 2014-06-30 Type: Warrant exercise Raised: DKK6.9 million ($1.3 million) Shares: 2.5 million Price: DKK2.78 Shares after offering: 145.8 million Investors: Company employees; company director Note: The...
BioCentury | Jul 14, 2014
Clinical News

Beleodaq belinostat regulatory update

...said details of the trial design have yet to be determined. Spectrum has rights from Topotarget...
...America and India. The approval triggered a $25 million milestone payment to Topotarget from Spectrum. Topotarget...
...is a small molecule dihydrofolate reductase (DHFR) inhibitor. Spectrum Pharmaceuticals Inc . (NASDAQ:SPPI), Henderson, Nev. Topotarget A/S...
BioCentury | Jul 3, 2014
Company News

FDA approves Spectrum's belinostat

...said details of the trial design have yet to be determined. Spectrum has rights from Topotarget A/S...
...million milestone payment to Topotarget from Spectrum. Spectrum was up $0.18 to $8.90 on Thursday. Topotarget...
Items per page:
1 - 10 of 329
BioCentury | Nov 19, 2014
Financial News

Onxeo proposes EUR 35.4M rights offering

...and Indian rights to Beleodaq, a small molecule histone deacetylase inhibitor. BioAlliance Pharma S.A. and Topotarget A/S...
BioCentury | Oct 6, 2014
Finance

3Q14 Stock Wrap-Up: Going big again

...combination with chlorambucil for first-line CLL in patients unsuitable for fludarabine-based therapy Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI)/Topotarget A/S...
BioCentury | Aug 18, 2014
Company News

Topotarget, BioAlliance deal

...Cancer companies BioAlliance and Topotarget completed their merger in a stock deal. The new company is...
...stock deal. The new company is Onxeo S.A. (Euronext:ONXEO, Paris, France) (see BioCentury, April 21). Topotarget A/S...
BioCentury | Aug 11, 2014
Company News

Innocutis, Onxeo sales and marketing update

...rights to the mucoadhesive formulation of acyclovir from Onxeo. Last month, BioAlliance S.A. merged with Topotarget A/S...
BioCentury | Jul 21, 2014
Company News

BioAlliance, EMS deal

...regulatory milestone payments. The companies could not be reached for details. BioAlliance is merging with Topotarget A/S...
BioCentury | Jul 21, 2014
Company News

Topotarget management update

...Business: Cancer Resigning: Anders Vadsholt as CEO, effective July 31 or until the approval of Topotarget’s...
BioCentury | Jul 14, 2014
Finance

Highlights of weekly biotech stock moves

...payment to partner Topotarget A/S (CSE:TOPO). Spectrum has North American and Indian rights to belinostat from Topotarget...
...company BioAlliance Pharma S.A. (Euronext:BIO). Spectrum finished Independence Day week up $0.89 (11%) to $8.90. Topotarget...
BioCentury | Jul 14, 2014
Financial News

Topotarget completes warrant exercise

Topotarget A/S (CSE:TOPO), Copenhagen, Denmark Business: Cancer Date completed: 2014-06-30 Type: Warrant exercise Raised: DKK6.9 million ($1.3 million) Shares: 2.5 million Price: DKK2.78 Shares after offering: 145.8 million Investors: Company employees; company director Note: The...
BioCentury | Jul 14, 2014
Clinical News

Beleodaq belinostat regulatory update

...said details of the trial design have yet to be determined. Spectrum has rights from Topotarget...
...America and India. The approval triggered a $25 million milestone payment to Topotarget from Spectrum. Topotarget...
...is a small molecule dihydrofolate reductase (DHFR) inhibitor. Spectrum Pharmaceuticals Inc . (NASDAQ:SPPI), Henderson, Nev. Topotarget A/S...
BioCentury | Jul 3, 2014
Company News

FDA approves Spectrum's belinostat

...said details of the trial design have yet to be determined. Spectrum has rights from Topotarget A/S...
...million milestone payment to Topotarget from Spectrum. Spectrum was up $0.18 to $8.90 on Thursday. Topotarget...
Items per page:
1 - 10 of 329